David Epstein Sells 250 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 250 shares of Tempus AI stock in a transaction on Monday, December 1st. The stock was sold at an average price of $75.55, for a total transaction of $18,887.50. Following the transaction, the director directly owned 26,421 shares in the company, valued at $1,996,106.55. This represents a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Tempus AI Stock Performance

TEM stock traded up $0.94 during midday trading on Wednesday, hitting $74.91. The company’s stock had a trading volume of 2,576,632 shares, compared to its average volume of 10,984,823. Tempus AI, Inc. has a 1 year low of $31.36 and a 1 year high of $104.32. The stock has a market cap of $13.33 billion, a price-to-earnings ratio of -62.95 and a beta of 4.99. The stock’s 50-day moving average price is $82.22 and its 200 day moving average price is $72.80. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. During the same period in the previous year, the firm earned ($0.46) EPS. The firm’s quarterly revenue was up 84.7% on a year-over-year basis. On average, equities analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current year.

Analyst Ratings Changes

TEM has been the subject of several research reports. Guggenheim increased their price objective on Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a report on Friday, September 26th. Canaccord Genuity Group decreased their price objective on Tempus AI from $110.00 to $95.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. TD Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 target price for the company. in a research report on Tuesday, October 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research note on Wednesday, October 8th. Finally, HC Wainwright reduced their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $81.17.

Institutional Trading of Tempus AI

A number of large investors have recently modified their holdings of TEM. Cranbrook Wealth Management LLC bought a new stake in Tempus AI during the third quarter valued at approximately $25,000. Concord Wealth Partners lifted its stake in Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares during the last quarter. JPL Wealth Management LLC purchased a new position in shares of Tempus AI in the 3rd quarter worth about $26,000. GAMMA Investing LLC bought a new stake in Tempus AI in the 3rd quarter worth approximately $28,000. Finally, Allworth Financial LP grew its position in Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.